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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is the end result of a susceptible individual being
exposed to sufficiently deleterious environmental stimuli. More than 90% of COPD-related deaths occur in low- and
middle-income countries (LMICs). LMICs face unique challenges in managing COPD; for example, deficient primary
care systems present challenges for proper diagnosis and management. Formal diagnosis of COPD requires quality-
assured spirometry, which is often limited to urban health centres. Similarly, standard treatment options for COPD
remain limited where few providers are trained to manage COPD. The Global Excellence in COPD Outcomes (GECo)
studies aim to assess the performance of a COPD case-finding questionnaire with and without peak expiratory flow
(PEF) to diagnose COPD, and inform the effectiveness and implementation of COPD self-management Action Plans
in LMIC settings. The ultimate goal is to develop simple, low-cost models of care that can be implemented in
LMICs. This study will be carried out in Nepal, Peru and Uganda, three distinct LMIC settings.
(Continued on next page)
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Methods/design: We aim to assess the diagnostic accuracy of a simple questionnaire with and without PEF to
case-find COPD (GECo1), and examine the effectiveness, cost-effectiveness and implementation of a community-
health-worker-supported self-management Action Plan strategy for managing exacerbations of COPD (GECo2). To
achieve the first aim, we will enrol a randomly selected sample of up to 10,500 adults aged ≥ 40 years across our
three sites, with the goal to enrol 240 participants with moderate-to-severe COPD in to GECo2. We will apply two
case-finding questionnaires (Lung Function Questionnaire and CAPTURE) with and without PEF and compare
performance against spirometry. We will report ROC areas, sensitivity and specificity. Individuals who are identified
as having COPD grades B–D will be invited to enrol in an effectiveness-implementation hybrid randomised trial of a
multi-faceted COPD self-management Action Plan intervention delivered by CHWs. The intervention group will
receive (1) COPD education, (2) facilitated-self management Action Plans for COPD exacerbations and (3) monthly
visits by community health workers. The control group will receive COPD education and standard of care treatment
provided by local health providers. Beginning at baseline, we will measure quality of life with the EuroQol-5D (EQ-
5D) and St. George’s Respiratory Questionnaire (SGRQ) every 3 months over a period of 1 year. The primary
endpoint is SGRQ at 12 months. Quality-adjusted life years (QALYs) using the Short-Form 36 version 2 will also be
calculated. We will additionally assess the acceptability and feasibility of implementing COPD Action Plans in each
setting among providers and individuals with COPD.
Discussion: This study should provide evidence to inform the use of pragmatic models of COPD diagnosis and
management in LMIC settings.
Trial registration: NCT03359915 (GECo1). Registered on 2 December 2017 and NCT03365713 (GECo2). Registered
on 7 December 2017. Trial acronym: Global Excellence in COPD Outcomes (GECo1; GECo2).
Keywords: COPD, COPD exacerbations, COPD case finding, COPD action plan, Non-communicable disease,
Self-management
Background
The global importance of COPD
Chronic obstructive pulmonary disease (COPD) is ‘a com-
mon, preventable and treatable disease that is character-
ized by persistent respiratory symptoms and airflow
limitation that is due to airway and/or alveolar abnormal-
ities usually caused by significant exposure to noxious par-
ticles or gases’ [1]. The primary risk factor for COPD in
high-income countries (HICs) is tobacco smoke exposure;
however, household air pollution (HAP), from burning
solid fuels such as wood, dung, agricultural crop waste,
and coal for energy, is the primary risk factor for COPD in
low- and middle-income countries (LMICs) [2]. In
addition to chronic progressive symptoms and functional
impairment, some individuals with COPD are prone to
intermittent deteriorations in respiratory health, or ‘exac-
erbations’, often driven by infection [3]. The global burden
of COPD is large and increasing. In 2015, it was estimated
that 174 million people worldwide had clinically signifi-
cant COPD, and an estimated 3.2 million individuals died
from the disease, an increase of 11.6% since 1990 [4].
COPD will become the third leading cause of death by
2030 [5]. Prevalence estimates vary due to different
methods of diagnosis; however, the BOLD studies report a
prevalence of moderate COPD or higher to be around
10% globally [1, 6]. Exacerbations are a major source of
morbidity from COPD, and the cause of direct healthcare
costs in high-income countries [7].
COPD in LMICs
More than 90% of COPD-related deaths occur in LMICs
[8]. The economic cost of illness due to COPD among
LMICs was estimated to be US$1 trillion in 2010 and is
expected to increase to US$2.6 trillion by 2030 [9]. In-
direct costs, including loss of productivity both by indi-
viduals affected by COPD and their caregivers, are
important in LMICs [9]. LMICs face unique challenges
when addressing COPD, including poorly resourced pri-
mary care systems and trained workforce shortages,
which present challenges with COPD diagnosis and
management, especially during exacerbations [10]. The
chronic nature of COPD means that people may access
multiple healthcare providers, including alternative
providers.
COPD case finding
The ‘gold standard’ method for diagnosis of COPD is
quality-assured, post-bronchodilator spirometry, though
COPD represents a range of phenotypes with different
symptomatic presentations including shortness of
breath, cough and sputum production [1]. In LMICs this
is often only available from pulmonary physicians in spe-
cialised urban centres, while most of the burden associ-
ated with this condition occurs in rural areas [10]. A
number of COPD case-finding questionnaires have been
validated in HIC settings, which are, therefore, likely to
be more sensitive to tobacco-associated COPD than
Siddharthan et al. Trials          (2018) 19:571 Page 2 of 15
biomass-fuel smoke [11–13]. In 2010, Yawn et al. devel-
oped and validated a simple five-item Lung Function
Questionnaire (LFQ) and compared this to standard
spirometry (area under the curve (AUC) = 0.720 with
sensitivity and specificity of 73.2 and 58.2%, respectively)
[11]. Martinez et al. combined peak expiratory flow
(PEF) measurements with a case-finding instrument to
improve the sensitivity, specificity and AUC for detect-
ing COPD (89.7%, 78.1%, 0.795, respectively) [12].
Case-finding instruments combined with low-cost
peak-flow meters could be useful tools for identifying in-
dividuals who should be further screened for COPD in
LMIC settings as well, although this has not been previ-
ously tested.
COPD self-management
Written self-management Action Plans are an integral part
of evidence-based management of COPD according to
international guidelines [1]. Action Plans support people
with COPD to recognise and react appropriately to exacer-
bations through initiation of additional pharmacotherapy
and modification of healthcare-seeking behaviours [14]. A
number of studies and systematic reviews have tested
self-management interventions for prevention and suc-
cessful treatment of COPD exacerbations in high-income
settings [15–19]. Bourbeau et al. demonstrated a 39.8% re-
duction in hospitalisations for exacerbations of COPD in a
multicentre randomised control trial of self-management
with comprehensive patient education compared to usual
care [14]. A similar trial by Effing et al. reviewed the effect-
iveness of self-management on the severity of exacerba-
tions and found a trend to fewer exacerbation days [20].
Finally, a 2005 Cochrane Review found that Action Plans
aid people with COPD in recognising severe exacerbations
and reacting appropriately to an exacerbation via the
self-initiation of antibiotics and/or orally administered ste-
roids [16]. The potential benefits, cost-effectiveness and
implementation challenges of Action Plans in LMIC have
not previously been studied.
Efforts to scale-up COPD case finding and management
are hampered by a shortage of specialised healthcare pro-
viders. Healthcare workforce shortages have been well
documented among LMICs and community health worker
(CHW) models of care have been widely utilised in health
priority areas including infectious diseases and nutritional
interventions [10, 21]. CHWs are a diverse category of
health workers who commonly work in communities out-
side of fixed health facilities and have formal, but limited,
training for the tasks they perform [21]. CHWs can serve
as a bridge between people and healthcare systems [22].
Many LMICs have existing CHW networks and a long his-
tory of implementing public health interventions utilising
CHWs to deliver health services [21]. CHWs are uniquely
qualified as connectors and tools of empowerment in
chronic disease management because they live within the
community in which they work [22–24].
Given the high and rising global burden of COPD, bet-
ter strategies to diagnosis COPD and manage exacerba-
tions are urgently needed for LMICs. In two linked
studies (Global Excellence in COPD Outcomes: GECo1
and GECo2), we aim to validate a modified COPD case
finding questionnaire (with and without PEF) to better
identify individuals for further screening for COPD, as
well as to develop evidence to support the wider imple-
mentation of COPD Action Plans among CHWs, allow-
ing for simple, low-cost models of COPD care in
LMICs. This study will enrol individuals in three distinct
LMIC regions, namely Nepal, Peru and Uganda.
Method / design
Goals
The over-arching goal of the GECo studies is to develop
simple, cost-effective models of COPD care that can be
implemented in LMICs. An overview of the studies is
shown in Fig. 1. Their schedule of enrolment, interven-
tions and assessments in shown in Fig. 2.
Objectives
The objectives of the present study are to validate
case-finding instruments with and without peak-flow mea-
surements in three diverse LMIC settings, and to develop
evidence supporting the effectiveness, cost-effectiveness
and implementation of a CHW-based strategy to deliver
self-management Action Plans for COPD.
Research questions
Primary research questions
1. GECo1: What is the diagnostic accuracy of case
finding for COPD using a questionnaire with and
without peak-flow measurements, compared to
gold-standard spirometry?
2. GECo2: What is the effect of a multi-faceted inter-
vention comprising a self-directed COPD Action
Plan delivered and supported by CHWs for the
management of COPD exacerbations on respiratory
health, and is this intervention likely to be imple-
mentable and cost-effective?
Implementation research questions
1. GECo1: What is the appropriateness, acceptability
and feasibility of using questionnaires to identify
COPD cases from the perspective of local community
Siddharthan et al. Trials          (2018) 19:571 Page 3 of 15
members, community health workers, local health
centre physicians and Ministries of Health?
2. GECo2: What is reach, adoption, implementation
and maintenance of a self-directed COPD Action
Plan strategy for management of COPD
exacerbations?
3. GECo2: How does the value for money of the self-
directed COPD Action Plan strategy vary by differ-
ent implementation constraints and for different
socioeconomic sub-groups?
Study design overview
GECo1 For the Case-finding study (GECo1) we will test
the diagnostic accuracy of case-finding instruments in
LMIC settings. To achieve the aim we will enrol a repre-
sentative community sample of up to 10,500 adults of
40 years of age and above in Nepal, Peru and Uganda
(Fig. 2). We will apply two modified questionnaires, with
and without PEF measurements, and compare perfor-
mance of this testing to spirometry, which will be
Fig. 1 Overview of the GECo Studies
Fig. 2 Schedule of enrolment, interventions and assessments
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conducted in the field according to the American Thor-
acic Society/European Respiratory Society (ATS/ERS)
standards using Easy-on-Air spirometers (ndd, Zurich,
Switzerland). The primary endpoint is area under the
receiver operating characteristics (ROC) curve. We will
report the sensitivity, specificity and ROC of case-
finding instrument with and without PEF compared to
standard spirometry.
GECo2 For the Self-management trial (GECo2), we will
randomise 240 adults (total for all sites) with grades B–D
COPD as per the GOLD 2017 classification, identified in
the case-finding phase, to an intervention or control arm.
We will develop and test a locally adapted, CHW-based
intervention strategy to improve self-management of
COPD (see ‘Description of intervention’). CHWs will be
instructed on chronic disease management for COPD, and
how to utilise the self-management Action Plan for man-
agement of exacerbations. We will measure quality of life
with the EuroQol-5D (EQ-5D) and St. George’s Respira-
tory Questionnaire (SGRQ) every 3 months over a period
of 1 year. The primary efficacy endpoint is the change in
the SGRQ at 12 months. Results of the EQ-5D will be
used to calculate quality-adjusted life years (QALYs) which
will inform the analysis of the cost-effectiveness and
equity impacts of implementation. We will additionally as-
sess the reach, adoption, implementation and mainten-
ance of Action Plans for exacerbations in each setting.
Settings
The study settings represent three distinct geographic and
economic regions in Asia, Latin America and Sub-Saharan
Africa. Inclusion of these countries will allow us to assess
varying degrees of urbanisation, environmental exposures
(i.e. tobacco and biomass-fuel smoke), and varying imple-
mentation contexts.
Nepal is a low-income country located in Southeast
Asia with a total population of 26.5 million, of which
82% is rural. Nepal’s GDP is £49 billion, with 25% of the
population living below the national poverty line. The
current ratio of physicians per person is 1:1742. The
current minimum wage is Rs 9700 per month (£66). The
study site is in Bhaktapur, 8 miles east of Kathmandu.
The majority of the estimated 80,000 inhabitants of
Bhaktapur municipality are either craftsman or business-
men, while many migrants come to work in the outskirts
at brick or carpet factories. CHWs, called female com-
munity health volunteers (FCHVs), are volunteers coor-
dinated by the Bhaktapur municipality to promote
community-based healthcare, health education and re-
ferrals. FCHVs are trained by their District Public Health
Office, under the Ministry of Health to serve within their
respective communities, mainly on family planning,
vaccination and nutrition programmes. There are ap-
proximately 90 FCHVs active in the municipality of
Bhaktapur and over 52,000 throughout Nepal.
Peru is an upper-middle-income country located in
South America with a population of 30.5 million, 10 mil-
lion of whom live in the capital (Lima), and 78.6% of
whom live in urban areas. Peru’s GDP is £145 billion,
and 26% of the population lives below the national pov-
erty line. The current ratio of physicians per person is
1:1116. The minimum wage in Peru is 850 soles per
month (£186). We will conduct this study in Pampas de
San Juan de Miraflores, a peri-urban community in south-
ern Lima, Peru’s capital. CHWs or ‘agentes comunitarios’
include community members who volunteer to support
health education programmes and campaigns at their cor-
responding health centre. The size of CHW networks and
specific duties and responsibilities can vary considerably
depending on the region, district, or health centre.
Uganda is a low-income country located in East Africa
with a total population of 37 million, and a large rural
population (> 80%). Uganda’s GDP is £19 billion with
19.5% living below the national poverty line. The study
will be carried out in the Nakeseke District of Uganda.
Most of the inhabitants (75%) are subsistence farmers
and over 60% of them live on less than 45,000 shillings
(£9) per month. The current ratios of physicians and
nurses per person are 1:25,000 and 1:5000, respectively,
making Nakeseke one of the most under-resourced
health districts in Uganda. CHWs called Village Health
Teams (VHTs) are selected in each village by the Uganda
Ministry of Health. They provide formal referral services
to local health centres and assist with community-based
follow-up. The VHT consist of community members
who volunteer for the position and are trained by the
Uganda Ministry of Health.
Study populations
We will enrol an age- and sex-stratified random sam-
ple of full-time residents of the proposed study areas
in Nepal, Peru and Uganda using existing census
data. Inclusion criteria are: aged ≥ 40 years; capable of
performing spirometry; and being a full-time resident
of the community. Full-time residence will be defined
as having lived in the study area for more than
6 months. Exclusion criteria are: self-reported preg-
nancy; having active pulmonary tuberculosis or being
on medications for pulmonary tuberculosis; unable to
do spirometry because of eye surgery, thoracic sur-
gery, abdominal surgery, or myocardial infarction in
the 3 months prior to study visit or a blood pres-
sure > 180/100 mmHg. For the self-management com-
ponent of the trial, we will enrol individuals who
were identified to have grades B–D COPD [1].
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Procedures case-finding phase (GeCo1)
Data collection
Demographic questionnaires will be applied to obtain so-
cioeconomic information, exposure history to cigarettes
and household air pollution, medical history and family
history of respiratory illness. Data will be collected by
trained field workers at each site and will be electronically
entered into REDCap using tablets with GPS capability
(Asus Z380M ZenPad, Taipei, Tawain) [25].
Lung Function Questionnaire (LFQ) We will adminis-
ter an instrument context-adapted from the original LFQ,
which has been validated in high-income countries, and
apply it to LMIC settings [11]. The LFQ assesses five
items: age, smoking history, wheeze, dyspnoea and phlegm.
The modified questionnaire will include additional items
including exposure to biomass fuel and will be adminis-
tered by field workers (see Additional file 1).
Capture CAPTURE is a simple five-item questionnaire
which, together with PEF, has been shown to be a viable
approach for COPD case identification in the US in pri-
mary care settings [12]. CAPTURE with PEF can identify
COPD patients who would benefit from currently avail-
able therapy and require further diagnostic evaluation,
and we will use this validated instrument and apply it to
LMIC. CAPTURE assesses five items: environmental ex-
posure, sensitivity to air quality/weather, how breathing
interferes with physical activities, comparing health with
peers, and exacerbations.
MRC Dyspnoea Scale and COPD Assessment Test
(CAT) At the case-finding visit, participants will be
asked to complete the modified Medical Research Coun-
cil Dyspnoea Score (mMRC) and the COPD Assessment
Test (CAT), which have been translated into relevant
local languages and previously validated. The mMRC
categorises self-perceived disability among those with
COPD on a five-item scale. The CAT is designed to
measure the impact of COPD on a person’s well-being
and daily life and is measured with eight items on a
40-point scale and will be administered to those with
COPD on spirometry.
Anthropometry and spirometry All participants will
have blood pressure, weight and standing height and
spirometry performed. Anthropometric measurements
will be recorded in triplicate and the median measure-
ments will be used for analysis. Systolic and diastolic
blood pressure measurements on the second and third
measurements will be averaged to calculate blood pres-
sure; the first measurement will be ignored to avoid po-
tential white-coat hypertension.
Trained study fieldworkers will conduct spirometry
using a flow-based portable spirometer to measure pul-
monary function and will record forced vital capacity
(FVC), forced expiratory volume in 1 s (FEV1), the per-
centage of FVC exhaled in the first second (FEV1/FVC),
and flow-volume curves. We will obtain at least three
acceptable manoeuvres in accordance with ATS/ERS
guidelines [26]. We will use the Global Lung Function
Initiative mixed ethnic population reference for calcula-
tion of percentage predicted values or Z-scores [27]. We
will test for reversibility (increase in FEV1 of ≥ 12% and
increase in FEV1 ≥ 200 mL) with two puffs from a salbu-
tamol inhaler (90 mcg/puff ) via a spacer. A COPD diag-
nosis will be defined as post-bronchodilator FEV1/FVC
below the lower limit of normal for that population fol-
lowing ATS/ERS standardised guidelines [26].
Spirometry quality control All spirometry will be read
by two independent reviewers locally who have been
trained in spirometry per ATS/ERS guidelines [27].
Spirometry that is deemed not acceptable or reprodu-
cible will be repeated up to one additional time. If there
is discrepancy in local reviewers over reads, the spiro-
gram in question will be reviewed centrally. Additionally,
10% or all curves will be independently reviewed cen-
trally for site-specific quality control. Spirometry will be
graded according to ATS/ERS classification and only
high- quality spirometry will be included for analysis
and trial recruitment [28].
Sample size and data analysis
Sample size The sample size required to estimate the
ROC area within 1.5% (based on a 95% confidence inter-
val), assuming an anticipated sensitivity of 90% and spe-
cificity of 60%, and assuming 11% of those screened will
have COPD is 9669 participants [2, 29]. To ensure an
adequate sample size is subsequently available for
GECo2, we will recruit a total of up to 10,500 subjects
(3500 at each site).
Analysis By site and overall we will summarise the char-
acteristics of those consenting to the study including
demographics, exposure history to tobacco and/or
household air pollution, anthropometric measurements,
spirometry measurements (FEV1, FVC and FEV1/FVC
ratio) and lung function scores (mLFQ, Capture, mMRC
dyspnoea scores).
Using a receiver operating characteristic (ROC) area
analysis, we will examine the diagnostic accuracy of the
questionnaire scores in identifying cases of COPD (com-
pared to spirometry). Curves will be obtained for the
mLFQ and CAPTURE questionnaires alone and then
each with addition of the PEF scores. Logistic regression
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models will be used to obtain the ROC curve and area
(AUC), with 95% confidence interval. Estimates will be
weighted based on census information from each site to
better reflect the population. A comparison between the
ROC areas will be made by site.
Self-management trial (GeCo2)
We invite participants with grades B–D COPD from the
case-finding phase to participate in the randomised con-
trolled trial in which they will be randomised to either a
multi-faceted intervention to promote adoption of
self-management of COPD exacerbations or continue to
follow usual care practices for COPD management. Full
study information will be provided and all patients will
provide written informed consent.
Randomisation
Once a participant is determined to be eligible and
agrees to enter the study, they will be randomised using
an online system (https://www.sealedenvelope.com/) at
each local site by the site-specific research team. The
computerised randomisation system will use 1:1 alloca-
tion to the enhanced support and usual care groups,
stratified by country and using random permuted blocks
of variable sizes. The assignment allocated to each par-
ticipant will be recorded in REDCap at local sites by the
local research team.
Blinding
Principal investigators and members of the data coordin-
ating centre will be blinded to treatment allocation.
Intervention arm
The intervention arm will receive (1) basic COPD edu-
cation, (2) CHW-delivered training in self-management
using a locally adapted Action Plan, (3) free CHW-
delivered rescue pack medications (steroid, antibiotic) for
acute exacerbations (as compared to free rescue medica-
tions from local health facilities in the control group). In
addition, the intervention arm will receive (4) monthly
home visits and (5) continuous access to a CHW with
expertise in educating, advising and reinforcing self-
management behaviours. (Table 1).
Control arm
The control arm will receive (1) basic COPD education
(see ‘Additional file 1’), (2) access to free medications
(steroids, antibiotics) for acute exacerbations available at
a local health facility and (3) access to usual care in the
local setting. Usual care is as follows per local practice:
Nepal Participants with grades B–D COPD will be re-
ferred to the local health centres in their respective
catchment areas. They will have access to their local
CHW per usual care, though this CHW would not have
had extra training or materials pertaining to
self-management Action Plans. If indicated by their
healthcare provider, medications will be provided by the
study team for COPD exacerbation from the Khwopa
Public Health Care Centre, our study site.
Peru Participants identified with grades B–D COPD
from the case-finding phase (GECo1) will be referred to
local health centres in their respective catchment areas.
If indicated by their healthcare provider, medications will
be provided by the study team for COPD exacerbations.
Uganda Participants with grades B–D COPD will have
access to their local CHW per usual care, though this
CHW would not have had extra training or materials
pertaining to self-management Action Plans. Participants
will be referred to local health centres in their respective
catchment areas. If indicated by their healthcare
Table 1 Multi-component strategy for self-directed management of chronic obstructive pulmonary disease (COPD) exacerbations
Component Description
COPD education
(control and intervention arms)
Basic COPD-specific education on (1) risk factors (e.g. household air pollution and tobacco), (2) symptoms and
disease progression and (3) how to avoid exacerbations and maintain general lung health (exposure reduction,
exercise, sleep and nutrition) using modified versions of standardised educational tools (e.g. ‘flip charts’)
administered by trained CHWs
Facilitated self-management
Action Plan
2-page Action Plans which colour-code states of respiratory health into green, yellow and red zones. (1) The
green zone describes the patient’s baseline respiratory symptoms and actions emphasise daily healthy
behaviour and harm reduction strategies, (2) The yellow zone denotes worsening dyspnoea and signifies an
exacerbation warranting use of inhaled bronchodilators and orally administered corticosteroids. If there is a
change in sputum quantity or colour the addition of antibiotics to corticosteroids is suggested,
(3) The red zone pertains to profound dyspnoea or associated symptoms including chest pain, fevers,
haemoptysis or change in mentation and urgent medical advice is recommended. Action plans will be facilitated
by contact with assigned community health workers
Monthly visitation by CHWs CHWs will reinforce concepts from the initial COPD education and the Action Plan during monthly visits. CHWs will
assess the individual’s ability to recognise symptoms and take appropriate action as indicated by the Action Plan
and will be trained to provide feedback and reinforcement accordingly. CHWs will provide additional rescue packs
to participants as needed
CHW community health worker
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provider, medications will be provided by the study team
for COPD exacerbation.
Formative phase
The intervention strategy was informed by the results of
formative research efforts conducted between July 2016
and October 2017. Formative research efforts included
in-depth interviews carried out among community par-
ticipants with COPD, CHWs and healthcare providers/
Ministry of Health officials across the three field sites.
As part of these efforts, we explored local terminology,
perceptions and explanatory models among community
members and healthcare practitioners, characterised the
supervisory and incentive structures of CHW networks
to determine feasibility of a CHW-delivered intervention
strategy in each setting, identified, categorised and
prioritised multi-level barriers and facilitators to target
using the COM-B/Behaviour Change Wheel framework
[30]. We then selected intervention functions and behav-
iour change techniques that targeted the key barriers to
adoption to arrive at our final intervention strategy.
Intervention design
This CHW-based intervention strategy centred on deliv-
ery of locally adapted self-management Action Plans was
designed to promote adoption of basic self-management
practices and health-seeking behaviours during an acute
exacerbation among individuals with COPD. Specifically,
the intervention is targeted toward modification of the fol-
lowing health behaviours: (1) monitoring and recognition
of warnings signs of a COPD exacerbation and (2) taking
prescribed rescue medications and/or seeks attention at a
health facility as indicated by evidence-based guidelines.
Intervention components
CHW-delivered COPD education All individuals
enrolled in the self-management trial (GECo2) (control
and intervention) will receive basic COPD education de-
livered by local CHWs. CHWs will provide
COPD-specific education on risk factors (e.g. household
air pollution and tobacco), symptoms and disease pro-
gression. Additionally, they will be advised on how to
avoid exacerbations and maintain general lung health
(exposure reduction, exercise, sleep and nutrition). We
will use modified versions of standardised educational
tools (e.g. ‘flip charts’), which have been previously de-
veloped and evaluated in Uganda [31]. Over the course
of the trial we will assess the delivery of the health inter-
vention through quarterly fidelity assessments which will
take place during monthly CHW visits.
Self-management Action Plan We developed the
COPD Action Plan based on existing Action Plans from
the UK National Health Service and the American Lung
Association for use in each of the three country sites
[32]. The Action Plan is identical across the sites, apart
from use of local language and illustrations. The Action
Plan includes instructions for symptom awareness and
medication self-management, with recommendations for
tobacco cessation and exposure reduction, pulmonary
rehabilitation, exercise, nutrition and sleep, and local
health centre contact information. Adaptation of the
educational tools (e.g. flip charts) and the COPD Action
Plan were informed by the results of formative research
efforts. We incorporated local terminology and tailored
visual representations of COPD risk factors, pathophysi-
ology, and symptoms to local context (Fig. 3). After the
creation of an initial prototype, we then solicited feedback
about Action Plan content and layout through consult-
ation with local healthcare practitioners and community
members across the sites and updated it accordingly.
Follow-up visits and reinforcement of self-management
practices by CHWs Follow-up visits by CHWs will
occur monthly for the intervention arm. During these
visits, CHWs will reinforce concepts from the initial
COPD education and the Action Plan. CHWs will assess
the individual’s ability to recognise symptoms and take
appropriate action as indicated by the Action Plan, and
will be trained to provide feedback and reinforcement
accordingly. Finally, CHWs will assess medication use
through self-report instruments and pill counts, and
provide additional rescue packs as needed. CHWs will
keep detailed records of contacts with participants.
Access to CHW-delivered rescue packs for acute ex-
acerbations Both the intervention and control arms will
receive access to rescue medications for COPD. CHWs
will deliver rescue packs (prednisone and antibiotics –
local choice) to intervention arm participants at the be-
ginning of the trial and as needed (Fig. 4). Control arm
participants will receive either free rescue packs from a
local pharmacy or be reimbursed for rescue medications
purchased during the trial, depending on local norms and
requirements. The efficacy of corticosteroids and antibiotics
for COPD exacerbations has been previously well docu-
mented. We intend to specifically assess the effectiveness of
a multi-faceted intervention to promote self-management
of COPD exacerbations at a community level. While both
study arms will receive medications for management of
COPD exacerbations, we hypothesise that a multi-faceted
strategy of self-directed care will lead to improved health
outcomes and be cost-effective.
Role of the CHWs
CHWs will deliver basic COPD education to all individ-
uals who are diagnosed with COPD in the case-finding
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phase (GECo1). CHWs will additionally support the
self-management action plan, of those participants re-
cruited to the self-management trial (GECo2) and ran-
domised to the intervention arm via monthly visits and
distribution of rescue packs for COPD when required.
The CHWs will have three roles:
Role 1: relevant during GECo1 and throughout the study
The CHW will deliver COPD education within 72 h
of COPD diagnosis via educational flip-charts. There
will be no mention of self-management Action Plans,
just basic COPD education delivery via flip charts
(see ‘Additional file 1’)
Fig. 3 Chronic obstructive pulmonary disease (COPD) self-management Action Plan. Action plans will be distributed to the intervention arm of
trial in addition to medication rescue packs. Sections are colour-coded (green – usual care, yellow – COPD exacerbation self-management, red –
urgent medical care)
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Role 2: relevant during GECo2
The CHWs will be trained by the research team to
support the self-management Action Plans. They will
be taught how to teach participants to use the Action
Plan; symptoms to be mindful of; and to remind par-
ticipants to partake of daily physical activity, eat well
and sleep well. They will also issue participants in the
intervention arm a rescue pack of antibiotics and ste-
roids, educate them when and how to take them and
reinforce that they are contactable daily for advice re-
garding COPD and self-management
Role 3: relevant during GECo2
The CHWs will conduct monthly visits to the
participants’ homes in the intervention arm
(approximately one participant per week per CHW).
At each visit they will reiterate the education listed
above and re-emphasise the role and use of the Action
Plan. They will re-stock medications if a rescue pack
has been used. They will record if a pack has been used,
when it was used, and whether the medications were
initiated correctly and the course was completed. They
will record what symptoms the participant experienced
that prompted them to take the medications in each
instance. Monthly visits by the CHWs to the interven-
tion arm participants to support the Action Plan will
occur to aid in promotion of behavioural changes
CHW training and health education
CHWs will be selected from local catchment areas and
trained on delivering health education related to COPD
based on willingness to participate. CHWs will
participate in a 2-day workshop consisting of health edu-
cation and role-playing which is harmonised across sites
(see ‘Additional file 1’). CHWs assigned to the intervention
component of the trial will additionally receive train-
ing on how to support individuals with COPD in
self-management of symptoms and exacerbations as
indicated in the Action Plans. CHWs delivering the
intervention arm will also be trained in medication
distribution, patient communication, navigation of
local health systems, and on delivering reinforcement
of self-management behaviours during follow-up
(Training plan included in the ‘Additional file 1’). A
COPD Knowledge Questionnaire will be applied be-
fore and after training to assess the effectiveness of
the delivered training to the CHW. CHWs will be
evaluated for a set of specific competencies before be-
ing approved to interact with study participants.
Training will be repeated twice through the study to
reinforce concepts taught in initial training and ad-
dress questions or concerns that arise during the
follow-up period.
Follow-up data collection
Data will collected by field workers at baseline and at
the 3-, 6-, 9- and 12-month follow-ups (from baseline)
(Fig. 5). The baseline data is as collected at the GECo1
visit. It is important to note that the 3-monthly visits
from the research staff are not the same as the monthly
CHW visits in the intervention arm.
St. George’s Respiratory Questionnaire (SGRQ) (primary
outcome)
The primary outcome of the trial will be a comparison of
the change in SGRQ from baseline to 12 months between
the two arms [33]. We will assess respiratory symptoms at
baseline, 3, 6, 9 and 12 months post randomisation using
the SGRQ. The SGRQ measures impaired health and per-
ceived well-being among individuals with chronic airway
disease and offers many advantages for our study, namely:
(1) can be used to quantify changes in health following
treatment, (2) it is not limited to individuals with COPD
and (3) it provides a standard metric that can be used for
easy comparison across our three diverse settings [33, 34].
The EuroQol-5D (EQ-5D) questionnaire will be col-
lected at baseline and quarterly through the trial period.
The EQ-5D is a generic instrument for describing and
valuing health. It is based on a descriptive system that de-
fines health in five dimensions: Mobility, Self-Care, Usual
Activities, Pain/Discomfort and Anxiety/Depression [35].
Each dimension has three response categories correspond-
ing to no problems, some problems and extreme prob-
lems. The instrument is designed for self-completion, and
respondents also rate their overall health on the day of the
Fig. 4 Rescue pack for chronic obstructive pulmonary disease (COPD) exacerbations. Medications based on GOLD recommendation for treatment
of COPD exacerbations and local prescribing practices
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interview from a 0–100 hash-marked, visual analogue
scale (EQ-VAS). Quality-adjusted life years (QALYs) will
be derived from the EQ-5D. The EQ-5D has been widely
tested and used in both general populations and patient
samples and has been locally validated in Nepal, Peru and
Uganda [35].
Health economics questionnaire We will collect de-
tailed information on health-related outcomes including
number of exacerbations, hospitalisations as well as
healthcare costs and health-related productivity costs at
3-monthly follow-up visits.
Medication use We will record pill counts of antibiotics
and steroids at quarterly follow-up visits and ask about
self-reported frequency and duration of respiratory
medications.
Sample size and data analysis
Sample size We calculated the sample size required for
this trial using a confidence interval approach justified
and described elsewhere [36]. This approach aims to en-
sure an adequate sample size to help inform a decision
about continuation of GECo2 to a main trial based on
an indication of a treatment effect for the primary out-
come. This SGRQ score has previously been shown to
have a standard deviation of 25 points in a similar popu-
lation and the clinically important difference is 4 points
(a recent Cochrane Review on the use of COPD Action
Plans found an average decrease of 4 points in SGRQ in
three randomised trials) [16]. A sample of 112 partici-
pants with COPD will be needed to produce an 80%
one-sided confidence interval that excludes a 4-point
difference in SGRQ under the scenario of no difference
in means. We expect to have sufficient subjects to enrol
240 participants from the GECo1 study.
Analysis The primary analysis will be a comparison
of SGRQ scores at 12 months between the rando-
mised groups. We will use multiple linear regression,
initially with adjustments for baseline SGRQ score
and country and in subsequent analysis with
adjustments for other factors including age, gender
and disease severity. We will estimate the difference
in means with a one-sided 80% confidence interval.
We will examine repeated measurements of SGRQ by
treatment group and fit random effects models to
consider the effect of the intervention over time. The
main analysis will be by intention-to-treat (ITT),
based on cases where the primary outcome is avail-
able and will, therefore, rely on an assumption that
data is missing at random. We will describe the num-
ber (%) with missing primary outcome, look at rea-
sons for missingness and consider characteristics of
the patients excluded from the ITT analysis. Models
will be rerun including adjustment for factors found
to be related to missingness of the 12-month score.
In pre-specified exploratory analysis we will examine
differences by site, and by existing vs. new diagnosis
of COPD.
Management
The core team (TS, SP, SQ, NR, WC, JH) report to a
Trial Steering Committee (TSC) that includes repre-
sentation from the funder, and other stakeholders.
Independent members (including the chair) are drawn
from our International Advisory Board. The TSC
meets 6-monthly. There is an independent DSMB
with one planned interim analysis examining safety
data, reporting directly to the TSC. Our other team
members run the Health Economics (MS, AM, MKC),
Implementation Research (SP, AC, SM) and Data (JB)
cores. Each site has a dedicated member of the core
team to provide initial support and assistance. Data
will be analysed biweekly by the Data core to assess
for missingness and outliers.
Economic evaluation
This analysis will primarily aim to evaluate the
cost-effectiveness of a multi-faceted intervention centred
on a self-management strategy for COPD exacerbations
within the effectiveness-implementation trial. However, in
an attempt to integrate implementation science concepts
with decision analysis, we will also incorporate health sys-
tem factors relating to service provision in the analysis for
Fig. 5 GECo 2 follow-up. Participants will be followed quarterly and queried on exacerbation history and healthcare utilisation. St. George’s
Respiratory Questionnaire (SGRQ) will be administered 6-monthly, EuroQol-5D and health-costing surveys will be administered quarterly
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each of the three settings and explore equity implications.
The main analysis will compare the health-related costs
and benefits of the COPD Action Plan plus education with
the health-related costs and benefits of default standard
care, as observed within the trial. Costs will be calculated
using the reported levels of resource use and multiplying
these estimates by the unit costs for each resource. The
EQ-5D results will provide estimates of the effectiveness
in terms of QALYs. QALY tariffs will be taken from
the country itself, when available, or from another
relevant source (e.g. adjacent country or international
average). Cost-effectiveness ratios will be reported as
the additional cost per QALY gained; however, these
will also be reported as additional cost per hospital-
isation and exacerbation averted to provide a clear
picture of the value of the intervention. As COPD is
expected to affect the labour status and productivity
of working-age people and their caregivers, we will
additionally explore the broader productivity benefits. The
main cost-effectiveness analysis will further include a sen-
sitivity analysis that accounts for the performance of the
case-finding questionnaire and which extends to the
short-term costs using assumptions and evidence of future
costs not captured within the GECo study.
To explore equity in the cost-effectiveness analysis,
we will assess whether there are population and indi-
vidual characteristics that enable some sub-groups to
gain more from the intervention than others. With
the benefit of intense follow-up and monitoring at
multiple time periods, we will be able to explore
whether the intervention provides equity benefits over
the course of implementation. Equity will be assessed
according by examining differences in the effective-
ness of the intervention according to socioeconomic
sub-groups. Within the trial, different health system
factors, or ‘constraints’, may hinder access, utilisation
or service provision and affect the cost-effectiveness
of the COPD Action Plan. Examples of constraints
include: access to drugs for the management of exac-
erbations and access to emergency care for severe
complications, which work through factors such as
health insurance coverage or distance to health facil-
ities. We will also identify constraints through the im-
plementation science outcomes related to acceptability
and feasibility. For this reason, the second part of this
work will explore how constraints interact with the
value of the COPD Action Plan, in the health system
in each setting.
The results from these analyses will be:
1) Establish whether the intervention is cost-
effective and to what degree it provides labour
and productivity benefits, thus informing deci-
sions for investment and scale-up
2) Identify important equity concerns so that any
trade-offs between maximising health and maximis-
ing fairness when scaling up the intervention are
made explicit, and
3) Identify the important health system constraints
that future implementation efforts should
consider in order to maximise COPD Action
Plan value
Implementation outcomes
Acceptability
We will conduct key informant in-depth interviews to
evaluate acceptability of the intervention from the per-
spectives of local community members, CHWs, local
healthcare professionals, and Ministries of Health over
the course of the trial. We will also ask individuals with
COPD to evaluate satisfaction with individual compo-
nents of the intervention in improving quality of life and
ability to manage their COPD quarterly.
Feasibility
We will solicit perspectives from the key groups men-
tioned above regarding the feasibility of the intervention
during planned in-depth interviews and focus group
discussions quarterly. In addition, we will record and
evaluate overuse of rescue packs, which can result in
antibiotic resistance and thus limit the feasibility of
use in these settings. We will also ask CHWs to
maintain a log of all visits, contacts from participants
and lengths of these interactions throughout the
follow-up period.
Fidelity
We will assess fidelity to the intervention during all
phases of implementation of GECo2. First, we will use
an LMIC-adapted version of the COPD-Q to assess
knowledge of COPD on the part of CHWs and study
participants to determine the effectiveness of the
COPD education curriculum [37]. We will administer
the questionnaire before and after the initial training of
CHWs and assess change in COPD-Q score to assess
score improvement. We will also administer this ques-
tionnaire to all study participants before and after their
initial education session with the CHWs, as well as
quarterly during follow-up visits to determine know-
ledge retention over time.
We will take attendance at all training sessions deliv-
ered to CHWs. CHWs will be expected to meet a set of
core competencies before being allowed to deliver
COPD education to study participants. Study team
members will also conduct observations of the initial
and follow-up visits by the CHWs. We will use check-
lists to determine fidelity to the intervention delivery
protocols at each stage.
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Ethics
Approvals: the trial has been reviewed and approved by
the University College London Research Ethics Commit-
tee (9661/001), Johns Hopkins School of Medicine
(IRB00139901), Uganda National Council for Science
and Technology, Makerere School of Medicine (SOM-
REC 2017–096), Nepal Health Research Council (136/
2017) and A.B. PRIMSA (CE2147.17). Additionally, the
trials have been registered at ClinicalTrials.gov (GECo1:
NCT03359915, and GECo2: NCT03365713).
Community consultation: community leaders were iden-
tified and approached to obtain permission to deliver the
interventions and conduct the evaluation surveys. Orien-
tation meetings were held to explain the project aims, and
community leaders will be invited to observe the random-
isation process at the start of the trial.
Consent: individual participation in any part of the
case-finding (GECo1) and/or self-management trial
(GECo2) will be on a voluntary basis, and participants can
choose to withdraw from either study at any time. Prior to
all data collection the purpose of the study will be ex-
plained, an information sheet will be provided, and con-
sent from the participant will be obtained. Respondents
will be told that they can decline to participate in the study
and can refuse to answer any question. Access to the iden-
tifiable individual-level data will be restricted to local study
staff. All participants provide signed informed consent.
There are risks concerning self-administration of
corticosteroids and antibiotics in the community set-
ting. The risk of administration of short-term cortico-
steroids is minimal and patients with a history of
pulmonary tuberculosis undergoing treatment will be
excluded. The largest risk with antibiotics is drug re-
action, though antibiotic resistance due to overuse is
an additional risk. Participants who experience a drug
reaction will be instructed to discontinue the medica-
tion and contact the local study investigator. Based
on the severity of reaction, they will be referred to
the local health centre. We will take detailed data re-
garding frequency and duration of all medication use
during the duration of the intervention.
Role of funder
This study is funded by the UK MRC (Medical
Research Council) under a Global Alliance for Chronic
Disease (GACD) call. Peer review of the original grant
application contributed to the final design of the study.
A representative of the funder is in attendance at the
TSC. The funder otherwise has no role in the conduct
or analysis of the study.
Dissemination
The results of the study will be submitted for publication
in peer-review journals, and for presentation at
international meetings. We anticipate two primary man-
uscripts reporting GECo1 and GECo2, and papers
reporting subsidiary analyses. Results will be presented
locally at each of our sites. Results will be used to for-
mulate policy documents to inform future provision of
care for people living with COPD. The GECo studies are
active on Twitter (@COPDGECo), and there is a trial
website (https://www.globalncd.org/geco-trial) providing
updates on progress.
Discussion
This paper describes the study protocol of the GECo
group: Implementation of COPD Case Finding and
Self-Management Action Plans in Low and Middle In-
come Countries. Study investigators will engage a diverse
set of stakeholders through this process including local
Ministries of Health, pulmonary specialists, primary care
physicians, CHWs and, importantly, individuals with
COPD to ensure that the stated interventions are accept-
able and appropriate to local environments. If successful
this study will increase our understanding of the efficacy
and implementation of case-finding and self-management
strategies in diverse sites in Asia, South America and
Sub-Saharan Africa with the aim of scaling this interven-
tion in a range of LMIC settings.
Trial status
The trial is on-going. Enrolment for GECo1 began on 5
January 2018 and GECo2 on 8 February 2018.
Additional file
Additional file 1: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents*. (DOC 254 kb)
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